Connect with us

Health Care

Exopharm Ltd (ASX:EX1) – Christopher Baldwin

Published

on

The CEO Mindset - Christopher Baldwin is the Chief Commercial Officer at Exopharm Ltd (ASX:EX1)

Christopher Baldwin is the Chief Commercial Officer at Exopharm Ltd (ASX:EX1), an Australian regenerative medicine biopharmaceutical company that is seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris™ and later a product called Cevaris™.

What’s your journey in becoming a CEO?
In my case, that’s still a work in progress! I see the journey as one from processes, to products, to people. As a chemical engineer and later as a consultant at McKinsey, I was most concerned with how complex systems functioned (or didn’t), how to diagnose them analytically, and how to move into better operations. I followed this with 10 years working across Asia Pacific leading commercial activities with hospitals and blood services. This is where I really learned the critical importance of well-designed, reliable products and how their value manifests in extremely diverse environments. Now, in the senior leadership at Exopharm, it strikes me every day how important people are. Helping them on their own journeys, keeping them engaged and pulling together, this becomes the true enabler of success.

Tell us a bit about your business and how you are commercializing?
We are on the cutting edge of a new biotechnology, the creation of medicines based on exosomes. Exosomes are the primary cell-to-cell communication network in the body, passing proteins, growth factors, and nucleic acids to orchestrate healing and repair. Our founding technology solved the challenge of isolating and purifying exosomes from blood and cell media. We are using this core technology to develop applications for a variety of diseases.

How are you managing with the current COVID-19 pandemic on both business and personal front?
This has been an extraordinary time. It has created considerable business disruption, of course, but once the noise settled, I found that it created a natural pause that allowed us to really take stock of where we were as a company and where we wanted to head. I would say we are more clear-minded, more ambitious, and have more opportunities than before. One example of this is Fortrexo COV, our approach to interrupting the progression of a coronavirus infection. This project has us excited and focused to apply the capabilities we have been assembling. Personally, I am grateful that family and close friends have not been seriously affected.

What’s the most exciting thing about running your business?
I find interacting with talented and committed people incredibly rewarding, and Exopharm is full of them! From our scientists to our business partners to our investors, we are surrounded by youthful geniuses, dedicated experts, and seasoned polymaths and entrepreneurs. Their curiosity and enthusiasm are infectious.

How do you measure success?
Genuine success only happens over years. Have we improved people’s lives, reduced their suffering, enabled their ambitions? From this perspective, genuine success is truly immeasurable. Of course, annual reports to shareholders would be quite slim if we insisted on measuring just that. For a company such as ours, success is best measured in the important milestones on the way to our objectives: clinical results, partnerships, patents and eventually, sales.

What do you think is the most important quality of being a CEO of a listed company?
Clarity. The world is full of opportunities, but not every opportunity is interesting for every investor or every employee. We have to be clear what we are trying to accomplish and how, so that each person can decide if they want to participate. Whether people are committing capital, time in their careers, or both to our company’s mission, it is important that they understand their choices as clearly as possible, and ultimately, that responsibility for clarity sits with the CEO.

What is your favourite book?
Cryptonomicon by Neal Stephenson, or just about anything else he’s written.

What message do you want to send to our readership in Asia?
Spend some time learning about exosomes – they weren’t in textbooks when you were in school, but they’ve been busy growing and repairing your body your entire life. They are truly fascinating and I think they will become very important to healthcare in the years to come.

How can people connect with you?
Email: chris.baldwin@exopharm.com
Company Website: https://exopharm.com/

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health Care

Q&A with StockPal – Althea Group Holdings (ASX:AGH)

Published

on

Q&A with StockPal - Joshua Fegan, CEO/Managing Director/Founder of Althea Group Holdings (ASX:AGH)

Watch Joshua Fegan, CEO/Managing Director/Founder of Althea Group Holdings (ASX:AGH) and Jared Sim, Editor-in-Chief and Co-Founder of StockPal in this engaging Q&A with the following questions:

0:08 – How did your company cope with the COVID-19 pandemic?
2:31 – When did the company list and why?
3:35 – How does your company make money?
4:22 – Who are your target customers?
5:23 What is your firm’s competitive advantage?

Visit Althea’s website to learn more about their story: https://althea.life/

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Health Care

Q&A with StockPal – Aptorum Group (NASDAQ:APM)

Published

on

Q&A with StockPal - Darren Lui, President and Executive Director of Aptorum Group (NASDAQ:APM)

Watch Darren Lui, President and Executive Director of Aptorum Group (NASDAQ:APM) and Jared Sim, Editor-in-Chief and Co-Founder of StockPal in this engaging Q&A with the following questions:

0:09 – How did Aptorum cope with the COVID-19 pandemic?
1:09 – When did Aptorum list and why?
2:50 – How does the company make money?
5:41 – Who are your target investors?
7:41 – What is Aptorum’s competitive advantage?
9:48 – What keeps you most excited about being in Aptorum?
12:50 – How do you measure success?

Visit Aptorum’s website to learn more about their story: https://www.aptorumgroup.com/

Email editor@stockpal.asia if you are or represent a listed-company and is keen to be in our interviews.

Continue Reading

Health Care

Q&A with StockPal – Antisense Therapeutics Limited (ASX:ANP)

Published

on

Q&A with StockPal - Mark Diamond, Managing Director & CEO of Antisense Therapeutics Limited (ASX:ANP)

Watch Jared Sim, Editor-in-Chief and Co-Founder of StockPal and Mark Diamond, Managing Director & CEO of Antisense Therapeutics Limited (ASX:ANP) in this engaging Q&A with the following questions:

0:16 – How did your company cope with the COVID-19 pandemic?
1:03 – When did the company list and why?
2:10 – How does your company make money?
3:05 – Who are your target customers?
4:13 – What is your firm’s competitive advantage?

Visit Antisense’s website to learn more about their story: https://www.antisense.com.au/

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Get more stuff

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

Recent Posts

Categories

Trending